Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| This represents its second consecutive year of growth since spin |
| And as you may recall from our third quarter earnings call, we guided to a very strong fourth quarter for our fertility business, based in part on a significant contract win with the largest PBM in the United States |
| Margins will likely be better in the second half compared to the first half as we implement those company-wide cost savings |
| We're optimistic that we can deliver on a third consecutive year of constant currency revenue growth that's also accompanied by some bottom line margin improvement and free cash flow of approximately $1 billion before one-time items |
| So overall, we believe it's a very solid sign that we can continue to drive to a billion dollars of free cash flow in this year |
| Our excess focus has been really very successful |
| This gives us ample financial flexibility to continue to service our dividend continue to execute on our business development agenda and to make progress towards achieving a net debt-to-EBITDA ratio of below four by the end of this year |
| That strong cash flow will provide financial flexibility to comfortably service our dividend, make progress on achieving leverage below four times by the end of 2024, and to continue to do business development in line with the types of transactions we have completed in the last couple of years |
| We're very proud of the business development we've completed today |
| Robust growth in key markets such as Canada and Brazil, and continued uptake of Hadlima in the U.S |
| Turning to Biosimilars on slide 12, biosimilars had a very strong fourth quarter, which was helped by favorable timing of Ontruzant, deliveries in Brazil to meet public sector demand |
| We expect another year of double-digit growth in our Biosimilars franchise, and we continue to demonstrate our ability to really ensure continued performance of our established brands business |
| We will also benefit from expected, continued recovery in China, as well as launches in select markets in the latter part of the year |
| And secondly, on Hadlima, again, pretty impressive growth leading all biosimilars versions |
| Our biosimilar products also continued to see strong demand and in established brands, volume growth outstripped pricing pressure during 2023 |
| In women's health, we had strong volume growth from fertility as well as from Jada |
| Volume growth for the year was approximately $420 million or about 7% higher than last year, and we saw volume growth across multiple franchises |
| So we feel very good about that |
| Just like in other parts of our business, we've been proving that in our hands and given proper focus, we can unlock additional value in our product portfolio |
| Nexplanon and Fertility are positioned for strong performance in 2024 |
| market leadership in covered lives within the fertility space after almost two decades |
| So we feel very strong about our performance |
| In the fourth quarter, we had some help by lapping a fourth quarter of last year that was significantly impacted by COVID, but fundamentally we're gaining share in China, primarily from domestic competitors, and we're seeing strong demand in the larger provinces |
| and China together represent about 60% of our fertility business, our Lamera region has also had a very strong 2023, in part due to new launches in the back half of the year that will help drive the high single-digit growth we expect from fertility business in 2024 |
| As you've heard from the discussion this morning, feeling very good about delivering our third year of constant currency growth as a stand-alone company |
| Fertility, Biosimilars and established brands all had very solid fourth quarters, which drove almost 9% volume growth during the period |
| And hopefully, that will start to really kind of generate some nice additional revenue growth for the Women's Health franchise as we go forward |
| Beginning on slide nine, you can clearly see in this year-over-year revenue bridge that the main driver of the 8% ex-FX revenue increase during the fourth quarter was solid volume growth |
| There's a tremendous opportunity in women's health to address significant unmet needs, and we're all well positioned at the forefront of that effort |
| Still, in 2023, Nexplanon surpassed the best-selling IUD to achieve the number one market share in a long-acting reversible contraceptive market in the U.S |
| Statement |
|---|
| In the full year Nexplanon results, you also see the impact of more limited participation in the tender in Mexico, as well as supply constraints in some fast-growing international markets like Asia and Africa that have since been resolved |
| Given that these volume drivers were one time in nature, the first quarter of 2024 is likely to be the lightest of the year for fertility, as inventory levels in the U.S |
| And rounding out women's health, as we spoke about last quarter in 2023, we made changes to the Nexplanon go-to-market model in the U.S., and we faced some headwinds outside the U.S |
| Also, most of our established brands portfolio has already been through VBP and has weathered those impacts |
| The year-over-year decrease in adjusted gross margin reflects higher costs of sales due to foreign exchange translation and product mix and to a lesser extent, higher post-COVID inflationary impacts on labor, materials, and distribution-related costs |
| And finally, based on current spot FX rates, FX could be a $50 million to $100 million headwind to revenue in 2024 or a range of 80 basis points to 160 basis points |
| Partially offsetting this solid volume growth was impact from loss of exclusivity, which in the fourth quarter was about $10 million and was primarily related to ongoing generic competition for NuvaRing in the U.S., and to a lesser extent, the LOE of Atozet in Japan |
| The year-over-year decrease was a result of lower adjusted gross margin |
| The year-over-year decline in net income is primarily due to higher interest expense associated with increased interest rates and accelerated amortization of capitalized financing costs associated with voluntary debt prepayments on the company's U.S |
| SG&A expense was down 3% and total R&D expense was down by 6% |
| When we spun out 2.5 years ago, there was -- there were inefficiencies around the company that we've been able to really kind of tailor down on |
| I know there's been a fair amount of investor confusion on what you guys are messaging exactly on dividend |
| It's much more difficult |
| LOE impact for the full year was about $20 million, and just like the fourth quarter, was driven mainly by ongoing generic competition for NuvaRing in the U.S |
| Moving on to price, we saw approximately $90 million of price erosion for the full year, and that was pretty equally driven by the familiar dynamics in established brands, the biosimilars portfolio, and fertility |
| The math on those collective headwinds would indicate that it's hard for us to envision a scenario that Nexplanon doesn't return to strong growth in the high single digits in 2024 |
| Turning to VBP, we expect VBP impact to be in the range of $30 million to $50 million for full year 2024, lower than what we saw in 2023 as we lapped the impact from Ezetrol and Remeron and HYZAARs inclusion |
| Outside the U.S., growth in 2023 was impacted by lower volumes from a public tender in Mexico |
| And in regards to your last question around free cash flow, it just essentially networking capital that we started to work greater on our focus on networking capital and more specifically around ERP costs started to come down a little bit less than we'd anticipated |
| And finally, you can see the approximate 190 basis points of financial reporting headwind we had in foreign exchange translation, which is a function of more than 75% of our revenue being generated outside the U.S |
Please consider a small donation if you think this website provides you with relevant information